Evidence map›Paper›PMID 24842338›Full record

ReviewThe American journal of gastroenterology2014

Toward a personalized medicine approach to the management of inflammatory bowel disease.

Mahmoud H Mosli, William J Sandborn, Richard B Kim, Reena Khanna, Bandar Al-Judaibi, Brian G Feagan

Abstract readReview
PubMed Publisher
In one paragraph

Review in The American journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Advances in Crohn's Disease: A Comprehensive Review of Pathophysiology, Diagnosis, and Emerging Therapeutics.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Engineering Precision Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019
    Review
  8. Review
  9. Accuracy of the new rapid test for monitoring adalimumab levels.Therapeutic advances in gastroenterology · 2019
    Article
  10. Article
  11. Article
  12. Review
  13. Biomarkers in Search of Precision Medicine in IBD.The American journal of gastroenterology · 2016
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. "Are you a gastroenterologist or a philosopher?".The American journal of gastroenterology · 2015
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Mahmoud H Mosli1] Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada [2] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada [3] Department of Medicine, Division of Gastroenterology, King Abdulaziz University, Jeddah, Saudi Arabia.
William J Sandborn1] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada [2] Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Richard B KimDepartment of Medicine, Division of Clinical Pharmacology, Western University, London, Ontario, Canada.
Reena Khanna1] Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada [2] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada.
Bandar Al-Judaibi1] Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada [2] Department of Medicine, Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
Brian G Feagan1] Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada [2] Robarts Clinical Trials, Robarts Research Institute, London, Ontario, Canada.
Western University · CAKing Saud University · SARobarts Clinical Trials · CAUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The medical management of inflammatory bowel disease (IBD) is evolving toward a personalized medicine-based model. Modern therapeutic algorithms that feature use of tumor necrosis factor (TNF) antagonists in combination with immunosuppressive are highly effective when initiated in high-risk patients early in the course of disease. Defined targets that guide intensification of therapy are critical interventions. In this model, therapy is optimized through appropriate pretreatment testing, therapeutic drug monitoring, and patient-based monitoring strategies. This review discusses the current application of personalized medicine to the management of IBD.

Indexed as

Precision MedicineAlgorithmsAzathioprineDrug MonitoringHumansImmunosuppressive AgentsInflammatory Bowel DiseasesMercaptopurineMethyltransferasesTumor Necrosis Factor-alphaAzathioprineImmunosuppressive AgentsMercaptopurineMethyltransferasesthiopurine methyltransferaseTumor Necrosis Factor-alpha

Identifiers

PMID24842338
OpenAlexW2072240642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.